Intervention not reported
Non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal myocardial infarction Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in non‐fatal macrovascular outcomes 1. Composite 2. Non‐fatal… (low certainty).
1 finding from 1 review
RR 1.08 [0.81, 1.45]
1 study · 2 participants
Low
Intervention not reported
Amphetamine use (UA) Negative urinalyses across the study · Amphetamine abuse or dependence
1 finding from 1 review
Intervention not reported
Mean improvement in pure‐tone average hearing threshold across all frequencies Decibels Scale from: 0 to 120 · patients with idiopathic sudden sensorineural hearing loss or tinnitus
1 finding from 1 review
Intervention not reported
ACR 50% improvement ‐ not measured · patients with treating rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
ACR 50% improvement ( · patients with Rheumatoid arthritis
The intervention showed no clear difference in ACR 50% improvement ( (low certainty).
1 finding from 1 review
Intervention not reported
Speed outcomes measured: Mean speed, 85th percentile speed, percentage of vehicles over the speed limit and percentage exceeding the speed limit by more than 15mph. Speed results across all new camera sites included a 2.3mph reduction (6% reductio...
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Crash outcomes measured: Killed and seriously injured (KSIs) and personal injury crashes (PICs). Across all sites KSI's decreased by 42%. This equated to about 1700 fewer KSI's per annum at these camera sites. Fixed cameras in both urban (47% redu...
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Having controlled for season and general trends, injury crash outcomes in experimental areas relative to control areas were a net reduction of 11% (p= 0.03) in all crashes and 19% (p=0.002) in injury crashes on open roads across the region associa...
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
ACR‐50 · patients with rheumatoid arthritis
1 finding from 1 review
ACR50% improvement criteria · patients with rheumatoid arthritis
Tocilizumab 8 mg/kg + MTX/DMARD leads to higher ACR50% improvement criteria compared with placebo + MTX/DMARD (high certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Golimumab 50 mg every 4 weeks + MTX leads to higher ACR50 compared with placebo + MTX (high certainty).
1 finding from 1 review
ACR 50 response of DMARDs naive patients Number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of DMARDs naive patients Number of responders compared with MTX monotherapy (low certainty).
1 finding from 1 review
ACR 50 response of MTX inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination probably leads to higher ACR 50 response of MTX inadequate responders number of responders compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
ACR 50 response of non‐MTX DMARDs inadequate responders number of responders · patients with rheumatoid arthritis
MTX combination showed no clear difference in ACR 50 response of non‐MTX DMARDs inadequate responders number of… compared with MTX monotherapy (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis
It is very uncertain whether MTX combination changes withdrawal due to adverse reactions (Pooled across regimens) number… compared with MTX monotherapy (very low certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis
Abatacept (2 and 10mg/kg) + DMARDs/biologic probably leads to higher ACR 50% improvement compared with placebo + DMARDs/biologic (moderate certainty).
1 finding from 1 review
ACR 50 response at 6 months · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide leads to higher ACR 50 response at 6 months compared with placebo, 6 months (high certainty).
1 finding from 1 review
ACR 50% improvement · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).
1 finding from 1 review
Caries experience (mean DMFT) · 12-year-old children across European countries (national/regional epidemiological surveys, 2011-2022)
Mean DMFT tended to increase with unemployment rate (low 1.23, medium 2.08, high 2.38; ANOVA p<.05); descriptive country-level means only, not meta-analyzed or GRADE-rated.
3 findings from 1 review
Caries experience (mean DMFT) · 12-year-old children across European countries (national/regional epidemiological surveys, 2011-2022)
Countries with higher per-capita dental expenditure had lower mean DMFT (>$100: 0.96; $51-100: 2.14; $0-50: 3.06) (Figure 4); not GRADE-rated.
3 findings from 1 review
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by OECD per-capita dental health-care expenditure (USD); test of group differences Q_b(2)=30.51, p<0.01; expenditure-stratified overall pooled DMFT 2.10 (95% CI 1.61-2.59), 32 countries · $0-50 per capita
MEAN 3.06 [2.32, 3.79]
14 studies
GRADE not reported
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by OECD per-capita dental health-care expenditure (USD); test of group differences Q_b(2)=30.51, p<0.01; expenditure-stratified overall pooled DMFT 2.10 (95% CI 1.61-2.59), 32 countries · >$100 per capita
MEAN 0.96 [0.64, 1.28]
12 studies
GRADE not reported
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by OECD per-capita dental health-care expenditure (USD); test of group differences Q_b(2)=30.51, p<0.01; expenditure-stratified overall pooled DMFT 2.10 (95% CI 1.61-2.59), 32 countries · $51-100 per capita
MEAN 2.14 [1.40, 2.89]
6 studies
GRADE not reported